BioSpace News Archive

Bicara Therapeutics today announced that company leadership will present at two upcoming investor conferences in November.

Artiva Biotherapeutics, Inc. today announced it has been awarded Immunology Innovation of the Year in the third annual BioTech Breakthrough Awards program, which conducts the industry’s most comprehensive analysis and evaluation of the top companies, solutions and products in the life sciences and biotechnology industry.

Strata Oncology announced that it is the recipient of the “Diagnostics Innovation Of The Year” award in the third annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products and services around the globe.

Gracell Biotechnologies Inc. announced that Gracell’s FasTCAR-T GC012F was selected as the winner of BioTech Breakthrough’s Overall Immunology Solution of the Year award.

Arthrosi Therapeutics, Inc. today announced new clinical data from its phase 2 AR882-203 study in patients with tophaceous gout.

Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the company will conduct an investor webcast on Tuesday, November 14, 2023 at 8:30 a.m. Eastern Standard Time to review third-quarter 2023 financials and provide corporate updates.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM”) today announced encouraging translational data from an ongoing Phase 2 clinical trial utilizing AIM’s drug Ampligen® in patients with platinum-sensitive advanced recurrent ovarian cancer.

NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced it has executed an exclusive option agreement with the University of Michigan for the exclusive licensing of its innovative rectal expulsion device (RED).

Surmodics, Inc. today reported financial results for its fourth quarter and fiscal year ended September 30, 2023, and introduced its financial guidance for the fiscal year ending September 30, 2024.

Vericel Corporation today reported financial results and business highlights for the third quarter ended September 30, 2023.